Within the last fess Xears. autologous mobilized peripheral blood cells have been substituted for autolocous bone marrow. to pros ide haematopoietic support after high-dose chemotherapy for a varietv of maliLnancies. includincz breast cancer (Gale et al. 1993 : Gratwohl et al. 1996 . Mobilized peripheral blood cells pros'ide more rapid recoxen-of neutrophils and platelets than bone marrow after high-dose chemotherapy. thus reducing the morbidity. the use of medical resources and the cost of transplant procedures (Faucher et al. 1994 : Hartmann et al. 1996 : Schmitz et al. 1996 ). Howesver. unmanipulated aphereses contain onlv a small proportion of progenitors. along w-ith subsets of differentiated and accessonr cells. and. in some cases. tumour cells : Brugaer et al. 1994a ): the latter appear to be mobilized bv chemotherapy and haematopoietic grosth factors to some extent (Brugger et al. 1994a) . Because aene markinu studies suggest that residual tumour cells in the graft may contribute to relapses occurring in a proportion of patients A-ith other malignancies (Brenner et al. 1993 : Deisseroth et al. 1994 . there is an incentisve to separate progenitors from other unnecessary cells present in the initial collection (Kennedv et al. 1991 : Shpall et al. 1991a . Human haematopoietic progenitors express the CD34-antigen (Andresws et al. 1992 : Link et al. 1996 : Bensinger et al. 1997 ). a sialomucin of unknosn function (He et al. 1992 : Simmons et al. 1992 . There is no clear demonstration so far that breast cancer cells express CD34. Therefore. selection of CD34+ cells may reduce or eliminate contaminating tumour cells from the graft. In addition to this purging' effect. CD34+ cell selection yields a well-characterized cell population -therefore producing a unique setting to study the relation between the number of infused progenitors and the haematopoietic recovery. Fmally. selection of CD34+ cells leads to cryopreservation of small numbers of cells in a small volume. containing a small amount of cryoprotective agent and may thus reduce both storage costs and side-effects associated with reinfusion of these cryoprotective agents such as dimethylsulphoxide (DMSO) (Shpall et al, 1997) .
Engraftnent after infusion of autologous selected CD34+ cellseither from bone marrow or mobilized blood cells -has alrady been reported (Berenson et al. 1991 : Brugger et al, 1994b : Shpall et al, 1994 : Gorin et al. 1995 : Schiller et al. 1995 : Civin et al. 1996 Lemoli et al. 1996 : Mahe et al, 1996 : Williams et al, 1996 : Hohaus et al, 1997 : Lopez et al, 1997 Mapara et al, 1997; Marin et al, 1997 : McQuaker et al. 1997 : Somlo et al, 1997 . These studies -including patients with breast cancer -demonstrated that haematopoietic recovery occurred after infusion of selected CD34+ cells. However, with one exception (Shpall et al. 1997) . a study based on the reinfusion of bone marrow cells, comparison with historical controls did not allow for the assessment of the influence of the selection process on the speed and durability of haematopoietic recovery, or of the incidence of side-effects. The present randomized multicentre study was designed to assess the safety and efficacy of using autologous selected CD34+ cells to support haematopoietic recovery following high-dose chemotherapy in patients with poor-prognosis breast cancer.
PATIENTS AND METHODS Patients
From November 1994 to December 1995. 71 patients entered a randomized multicentre study designed to evaluate the safety and efficacy of selected peripheral blood CD34+ cells, to support autologous haematopoietic recovery after high-dose chemotherapy for poor-prognosis breast cancer. All patients had histologically documented adenocarcinoma of the breast: patients were considered to be at high-risk because they had metastatic disease, or because they had more than eight positive nodes. and were thus eligible for institutional protocols using dose-intensified chemotherapy with haematopoietic cell support. The study was reviewed and approved by the Comite Consultatif de Protection des Personnes dans la Recherche Biomedicale (CCPPRB) in Marseilles. for French centres. and by Institutional Review Boards at US institutions. All patients gave informed consent before entering the study. All patients were assigned a study number, but were not randomized until time of successful mobilization, as defined below.
Collection of peripheral blood stem cells (PBSCs) Peripheral blood progenitors were mobilized with a variety of regimens, according to institutional protocols: in most cases, it included high-dose cyclophosphamide (see Table 1 ). followed by the daily administration of recombinant human granulocyte colony-stimulating factor (rhG-CSF) (Neupogen. Amgen. Thousand Oaks. CA. USA) 5-10 jig kg-' or 300 jg subcutaneous. until collection of mobilized blood cells. At Indiana University. patients were mobilized with rhG-CSF alone (10 gog kg-' day-').
Because a variety of mobilization regimens were used. a standard criteria for successful mobilization was established: apheresis was started when the absolute number of CD34+ cells in the peripheral blood rose above 20 gl.-' Patients who failed to reach this threshold were excluded. Patients who successfully mobilized were randomized at that time to the control arm or the test arm. using a computer-generated random assignment list for each participating medical centre. Randomized patients were further analysed on an intent-to-treat basis. unless otherwise indicated.
Aphereses were performed with an automated processor (CS3000®. Baxter-Fenwal Division. Deerfield. IL, USA. or Cobe Spectra®. Lakewood, CO. USA), and approximately two blood volumes were processed during each 3-to 4-h session. Aphereses were repeated on a daily basis until the equivalent of at least 2.5 x 106 CD34+ cells kg-' were collected for patients in the control arm. and at least 6.5 x 106 CD34+ cells kg-' were collected for patients in the study arm (of which S x 106 CD34+ cells kg-' were used for cell separation and 1.5 x 106 CD34+ cells kg-' were cryopreserved unmanipulated as aback-up). Patients who failed to reach these thresholds were removed from the study. These figures were based on reports that were available at initiation of the study.
regarding the minimal number of CD34+ cells that ensures optimal engrafment (Bender et al, 1992; Bensinger et al. 1994 : Haas et al. 1994 van de Wall et al, 1994; Faucher et al. 1996) . and on the assumption that the yield of the cell separation procedure would be approximately 50%, thus providing for similar numbers of progenitors in both groups.
Selection of CD34+ cells CD34+ cells were separated from apheresis products. using the Isolex®300 device according to the manufacturer's instructions. with chymopapain as an agent to release immunomagnetic beads from target cells (Civin et al. 1996; Hohaus et al. 1997; Mapara et al. 1997) . When CD34+ cells had to be separated on the day following apheresis, cells were stored overnight at 4°C or at room temperature. In brief, the cells were centrifuged at low speed to deplete platelets, and washed once with a buffer solution containing 1% (v/v) human serum albumin. The volume was adjusted to 100 ml. and 0.5 g of human immunoglobulin was added. Clinical grade murine class H anti-CD34 antibody (9C5) was also added to a final concentration of 0.5 jg 10-6 nucleated cells. After a 15-min incubation, the cells were washed once with a buffer solution, and transferred to the Isolex® disposable chamber, and the volume adjusted to 300 ml. An additional 0.5 g of human immunoglobulin and one vial of prewashed sheep anti-mouse IgGcoated paramagnetic beads (Dynabeads® M-450. Dynal) was added to the chamber. Following 30 min of incubation, the nontarget (CD34 'minus') cells were drained from the chamber, and the target CD34+ cell-bead complexes were washed three times with a buffer solution. The cells were released from the beads by the addition of 8000 pkat clinical grade chymopapain (ChymoCell-T). which cleaves a chymopapain-sensitive epitope recognized by the 9C5 monoclonal antibody on the CD34 molecule (Greaves et al. 1995) . followed by a 15-min incubation. The CD34+ cells -free of beads -were drained from the chamber and washed before cryopreservation.
Selected and unselected cell products were cryopreserved according to institutional procedures with 10% DMSO. using controlled rate freezing. with the exception of Texas Oncology PA in Brifish Jourmal of Cancer (1998) 78 (7), [913] [914] [915] [916] [917] [918] [919] [920] [921] Dallas (this centre contributed seven patients: Table I ). where a pentastarch cryopreservation solution and dump freezing were used.
The percentages of CD34-cells and other cell subsets were estimated before and after the separation. using, immunofluorescence and flow cvtometrv. according to institutional protocols. HPCA-2 (Becton Dickinson. San Jose. CA. USA). a class III anti-CD34 monoclonal antibodv that recognizes a chymopapain-resistant epitope (Greaves et al. 1995) 
Tumour cell contamination
The presence of epithelial tumour cells in aphereses and after CD34-cell selection w-as independently assessed for all centres at BIS Laboratories (Reseda. CA. USA) Ross. 1992: Ross et al. 1993 ). using cryopreserxed cell samples that were collected at and sent from each participating institution. Cy'tospin slides were prepared. and at least 106 cells w-ere examined. Tumour was expressed as a per cent recovery of the amount added. Patient results were reported as falling into one of the followingy three categories: negatixe (< 74ng, ml-'). positixe (74-440 n ml-') or strongly positive (> 440 ng ml-' ).
A similar ELISA assay x-as used to determine whether HASA was present. A ratio R xas established between the sample and a normal control. The samples were scored as follows: if the sample was 1.0 < R < 2.5. the sample was considered negative: if 2.5 < R < 7.5. the sample was considered positixe: 7.5 < R < 10.0 xxas clas- Statistical analyses Statistical analy ses were carried out. using the SAS statistical software package. All statistical tests were two-sided. and a significance level of 0.05 xxas used to judge statistically sianificant test The primary safety objectix e wxas to determine w-hether infusion of CD34+ isolated from mobilized blood cells results in any unusual or unexpected toxic side-effect oxer those observed after infusion of unselected mobilized blood cells. The incidence of serious and unexpected side-effects wxas calculated for each treatment group. and Fisher's exact test used to assess treatment differences. The incidence of infectious episodes with or w-ithout documentation (culture) was calculated for each treatment group. Secondarv safety parameters included days of hospitalization following chemotherapy. days of antibiotic usage and number of transfusions required for each group.
RESULTS

Patient characteristics and blood cell mobilization
A total of 71 patients were entered in the study from Noxember 1994 to December 1995. at six different medical centres. usinc the Isolex9300 device to separate CD34+ cells from aphereses. Of the 71. 24 patients were not randomized. 15 because they failed to meet the mobilization criteria (the number of circulating CD34-cells did not reach 20 t1'). and nine because of a varietx of events (two patients had progressive disease. three patients had medical complications before randomization. one patient was assirned a number in error. one patient xoluntarilv withdrew from the studv before randomization and two patients were not monitored for mobilization). The other 47 patients reached the threshold of 20 CD34+ cells pA-' of circulating blood. and were randomly assigned either to the test group (n = '6). or to the control group (n = 21).
British Joumal of Cancer (1998) 78(7). 913-921 Cell selection: progenitor cell recovery and tumour purging British Joumal of Cancer (1998) 78(7), 913-921 (Table 6 ). To eliminate the possibility that the fixve patients w-ho received a back-up product (unselected apheresis cell products) in the test group may haxe biased the engraftment data. a subset of the test group including, the 21 patients w-ho received only CD34-cells was analysed. Conclusions remained unchanged. with no difference between the subset and the control group in terms of neutrophil or platelet engraftment. There has been no report of long-term marro%v dysfunction.
There was no difference betu-een the test group and the control aroup in the reported incidence of any adverse effect associated w-ith infusion (reported according to the NCI common toxicity criteria). The number of infectious episodes w-as identical in both groups. with 57%c in the control group and 54%e in the test grroup (Table 7) : there was also no difference in the severitv of infectious episodes: this is supported by comparable antibiotic usage in both groups. One patient in the control garoup had two episodes of fungal infections. and one episode of xiral infection: no other documented opportunistic infection was reported. No infusional toxicity in the test group w as considered to have any relationship w-ith the use of the cell selection device. Analy1sis of variance to compare the maximal changes in xital sigrns (respiration. pulse. temperature. diastolic and syvstolic blood pressure) from before infusion to after infusion indicated no difference between the tu-o groups. Serum samples from 11 patients in the test aroup and 11 patients in the control group were checked for the presence of HAMA and HASA. and were found to be negatixe at baseline and after transplantation. except for one control patient w ho A as positive for HASA at both time points.
Thirteen of 26 test patients and 13 of 21 control patients haxe been reported to hax-e relapsed. There has-e been four reported deaths of patients durinc the first 6 months after transplant. three in the test group and one in the control group. All had progressive disease. There have been eight additional deaths reported in the long-term follow--up. four in each roup. How-ever. it should be noted that tw o of the relapses and deaths in the test arm occurred in patients who received back-up unselected products. In order to better assess the potential effect of positive CD34-cell selection on relapse and death. w e have reanaly sed these parameters.
comparing the control group w-ith the test subset. excludinc the five patients who received unselected back-up PBSCs: this did not change conclusions. At more than 1 yvear of follow-up for most patients (median follow-up of 344 days). there is no significant difference in terms of event-free or oxverall survixal betxeen the control and test groups. and no pattem suggestive that the test group is at greater risk.
British Joumal of Cancer (1998) 78(7) (Somlo et al, 1997) , but this was not statistically significant, nor did it translate into more adverse events, or additional requirements for platelet transfusion. These observations were obtained in a heterogeneous cohort of subjects with poor-prognosis breast cancer, which reflects, however, the reality of medical practice in this field, and the lack of standards of care for these patients. In addition, characteristics of patients were equally distributed in the test group and in the control group, and the study designincluding randomization stratified by participating centreallowed for the power to detect a 3-day difference in the time to neutrophil engraftment.
It is clear that CD34+ cell selection results in a significant loss of progenitors. Whereas the study was initially designed so that patients in the study group and patients in the control group should have received comparable numbers of CD34+ cells, analysis of infused cell counts showed that this was not the case. The 26 patients in the study group received a significantly lower number of CD34+ cells than did the 21 patients in the control group, despite a significantly higher number of aphereses in the former. These observations reflect both the difficulty during apheresis of collecting accurately a predefined number of cells (e.g. more than 2.5 x 106 CD34+ cells kg-' were collected for most control patients), and the loss of cells during the separation procedure. It is interesting that the number of CD34+ cells that were infused in patients in the study group was below the threshold that we (Faucher et al, 1996) and others (Bender et al 1992; Bensinger et al, 1994 : Haas et al, 1994 Weaver et al 1995) considered as the minimal number necessary to ensure the quickest haematological recovery with unselected PBSCs; on the other hand, patients in the control group received on average a number of CD34+ cells that was close to or above this threshold. The loss of progenitor cells may explain the delay in platelet recovery observed after transplantation of autologous marrow CD34+ cells, which was previously demonstrated (Shpall et al, 1997) . It is also clear from our observations that before cell selection one has to use the best mobilization regimen that is available: because chemotherapy and haematopoietic growth factors usually result in a better mobilization than haematopoietic growth factors alone, the fonner may be the preferred choice for this kind of treatment strategy; indeed. there was an excess of patients mobilized with rhG-CSF alone in the group of patients who failed to meet the mobilization criteria compared with the group of randomized patients. The use of rhG-CSF alone in a previously published study (Mahe et al, 1996) resulted in an average number of infused CD34+ cells that was lower than in the present study, especially for the subset of myeloma and lymphoma patients who had already received more than three courses of chemotherapy. Fmally, patients who have a medical history that predicts a poor ability to mobilize blood progenitors -such as a high number of previous chemotherapy cycles (Bensinger et al, 1994; Haas et al, 1994; Chabannon et al, 1995 : Mahe et al, 1996 -may not be good candidates for cell selection, unless the yield of CD34+ cells can be improved; although the difference was not statistically significant, there were more patients who had received three or more chemotherapy regimens before inclusion in the group of patients who failed to reach the threshold of 20 circulating CD34+ cells 11-l of blood (non-randomized patients).
Tlhe feasibility of CD34+ selection has already been demonstrated, both for patients with breast cancer and for patients with other malignancies (Berenson et al, 1991; Brugger et al, 1994b; Shpall et al, 1994; Gorin et al, 1995; Schiller et al, 1995 : Civin et al, 1996 Lemoli etal, 1996; Mahe etal, 1996; Hohaus et al, 1997; Lopez et al, 1997; Mapara et al, 1997; Marin et al, 1997: McQuaker et al, 1997; Somlo et al, 1997) . The most recent studies describe the use of apheresis products (Brugger et al, 1994b; Schiller et al, 1995; Lemoli et al, 1996; Lopez et al, 1997; Mahe et al, 1996; Hohaus etal, 1997; Mapara etal, 1997; Marin et al. 1997; Somlo et al, 1997) , whereas older publications are based on the selection of CD34+ cells from marrow collections (Berenson et al. 1991; Shpall et al, 1994; Gorin et al, 1995; Civin et al, 1996; Lopez et al, 1997; Shpall et al, 1997) . Also, only three publications (Civin et al, 1996; Hohaus et al. 1997; Mapara et al, 1997) describe the use of a biomedical device similar to the one used in this study. Except for one study with marrow grafts (Shpall et al. 1997 ) none of these studies was a randomized study, and haematological recovery was compared with historical controls. We here provide additional evidence that CD34+ cells can be safely selected from apheresis products. Because aphereses contain a higher number of haematopoietic progenitors than marrow harvests, it is likely that the consequences of the loss of CD34+ cells during the procedure will have less influence on autologous haematopoietic recovery.
Tumour purging evaluation was difficult for several reasons.
First, the frequency of positive aphereses is low (equal or lower than in the bone marrow), even in a population of patients treated at an advanced stage of their disease; the significance of this low frequency, and the most appropriate technique to be used for tumour cell detection in breast cancer remain to be determined (Mapara et al, 1997) . Our observations consistently demonstrate the possibility of detecting as few as one epithelial tumour cell in 105 to 106 assayed cells, and the percentage of positive aphereses and patients in our series is consistent with data already published Brugger et al, 1994a; Jones, 1994 : Hohaus et al. 1997 ; only one recent report suggests a much higher frequency of positive aphereses in advanced breast cancer patients (Mapara et al, 1997) . Second, the clinical consequences of tumour purging are difficult to assess on such a small number of subjects, and are unlikely to be apparent in a population of patients who mostly had advanced metastatic disease. In two evaluable patients, detection of epithelial tumour cells among progenitors, before and after separation, showed that purging was considerable, albeit partial. resulting in the reinfusion of a very small number of tumour cells; this small number is to be compared with the high tumour burden that characterized all of our patients at the time of high-dose chemotherapy. The observation that detection of bone marrow micrometastases using PCR is a strong adverse prognostic factor (Fields et al, 1996) suggests that eradication of the endogenous disease remains the most important hurdle in the area of metastatic breast cancer chemotherapy. Tlhe clinical consequences and potential advantages of tumour purging will now need to be evaluated in larger cohorts of patients, and are likely to be more apparent in a British Jourmal of Cancer (1998) 78 (7), 913-921 population of subjects that are transplanted with a lower tumour burden. such as in the adjuvant setting. However, because the prognosis of this patient population is much better than for patients with metastatic disease. it is likely that this evaluation will require a large number of patients and long-terrn follow-up. Analysis of the outcome of patients in both groups showed no difference in terms of relapse rate and event-free survival. As could be expected from the characteristics of this group of patients. relapse occurred frequently and early after transplantation. and progressive disease accounted for all recorded deaths. This emphasizes the need for better chemotherapy regimens in patients with poor-prognosis breast cancer (the present study was however designed to evaluate a new transplant technique. and not the use of high-dose chemotherapy for the treatment of advanced or poor-prognosis breast cancer). and again the need to choose a different population of patients to evaluate the consequences of tumour purging, once the safety of using selected blood CD34+ cells is definitively established.
In conclusion, we were able to select safely CD34+ cells from aphereses collected in patients with poor-prognosis breast cancer. Our randomized study demonstrates that selected CD34+ cells support haematopoietic recovery after high-dose chemotherapy in these patients, in a time period similar to that observed in patients receiving unmanipulated autologous mobilized blood cells. despite the loss of progenitors during ex vivo cell processing. but thus at the expense of one additional apheresis. As the demonstrable clinical benefits associated with positive selection may be relatively small compared with the many risks associated with high-dose chemotherapy and progenitor cell reinfusion. it was important to demonstrate that the risks associated with the use of a cell selection device are relatively small. Our observations prepare the way for future trials designed to evaluate the clinical benefits associated with CD34+ cell selection.
